No Metabolic Risk for Antipsychotic-Naive Patients


An Austrian study of the baseline prevalence of metabolic abnormalities and changes following treatment with five commonly-used antipsychotic drugs (haloperidol, amisulpride, olanzapine, quetiapine or ziprasidone) in first-episode, partially antipsychotic-naive patients with schizophrenia found that the overall prevalence was similar to the rate seen in both antipsychotic-naive patients and the general population. The study, published in the International Journal of Neuropsychopharmacology, found that metabolic risk increased significantly in all groups over the 52-week followup.

Abstract →

Fleischhacker WW, Siu CO, Bodén R, Pappadopulos E, Karayal ON, Kahn RS; Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. International Journal of Neuropsychopharmacology. 2012 Dec 20:1-9. [Epub ahead of print]

Previous articleOutpatient Commitment Would Harm Patients in Need
Next articleSudden Death of a Relative in Early Childhood Increases Risk of Psychotic Disorder
Kermit Cole
Kermit Cole, MFT, founding editor of Mad in America, works in Santa Fe, New Mexico as a couples and family therapist. Inspired by Open Dialogue, he works as part of a team and consults with couples and families that have members identified as patients. His work in residential treatment — largely with severely traumatized and/or "psychotic" clients — led to an appreciation of the power and beauty of systemic philosophy and practice, as the alternative to the prevailing focus on individual pathology. A former film-maker, he has undergraduate and master's degrees in psychology from Harvard University, as well as an MFT degree from the Council for Relationships in Philadelphia. He is a doctoral candidate with the Taos Institute and the Free University of Brussels. You can reach him at [email protected].